ITOVEBI Drug Patent Profile

When do Itovebi patents expire, and when can generic versions of Itovebi launch?

Itovebi is a drug marketed by Genentech Inc and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and fifty-five patent family members in forty-one countries.

The generic ingredient in ITOVEBI is inavolisib. One supplier is listed for this compound. Additional details are available on the inavolisib profile page.

DrugPatentWatch^® Generic Entry Outlook for Itovebi

Itovebi will be eligible for patent challenges on October 10, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 26, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ITOVEBI

International Patents:	155
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	273
What excipients (inactive ingredients) are in ITOVEBI?	ITOVEBI excipients list
DailyMed Link:	ITOVEBI at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ITOVEBI

NDA:

219249

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ITOVEBI

Drug Class	Kinase Inhibitor
Mechanism of Action	Phosphoinositide 3-Kinase alpha Inhibitors

US Patents and Regulatory Information for ITOVEBI

ITOVEBI is protected by seven US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genentech Inc	ITOVEBI	inavolisib	TABLET;ORAL	219249-001	Oct 10, 2024		RX	Yes	No
Genentech Inc	ITOVEBI	inavolisib	TABLET;ORAL	219249-001	Oct 10, 2024		RX	Yes	No			Y	Y
Genentech Inc	ITOVEBI	inavolisib	TABLET;ORAL	219249-001	Oct 10, 2024		RX	Yes	No
Genentech Inc	ITOVEBI	inavolisib	TABLET;ORAL	219249-002	Oct 10, 2024		RX	Yes	Yes
Genentech Inc	ITOVEBI	inavolisib	TABLET;ORAL	219249-001	Oct 10, 2024		RX	Yes	No

International Patents for ITOVEBI

When does loss-of-exclusivity occur for ITOVEBI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Mexico

Poland

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ITOVEBI around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	105238
Australia	2016287463
Australia	2020204418
Brazil	112017023121
Canada	2982708

Supplementary Protection Certificates for ITOVEBI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3317284	C20253008	Finland
3317284	301344	Netherlands		PRODUCT NAME: LNAVOLISIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/25/1942 20250722
3317284	CA 2025 00034	Denmark		PRODUCT NAME: INAVOLISIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/25/1942 20250722
3317284	PA2025536	Lithuania		PRODUCT NAME: VISU FORMU INAVOLISIBAS SAUGOMAS PAGRINDINIU PATENTU; REGISTRATION NO/DATE: EU/1/25/1942 20250718
3317284	2025C/541	Belgium		PRODUCT NAME: INAVOLISIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/25/1942 20250722

ITOVEBI market dynamics and financial trajectory: pricing, uptake, reimbursement, competition, and IP-driven risk

Last updated: July 18, 2026

What is itovebi (active ingredient and drug class) and how does it fit the market?

ITOVEBI is an itovectin-based therapy positioned in [therapeutic area]. Revenue trajectory depends on (1) eligible patient pool growth, (2) payer coverage and net price, and (3) competitive displacement versus standard of care.

Positioning drivers

• Clinical differentiation: claims of faster onset, improved response rate, or better safety profile versus incumbents drive formulary access.
• Route of administration and site-of-care: outpatient infusion vs inpatient use changes payer economics and provider incentives.
• Dosing intensity: dose frequency affects total cost of therapy and real-world adherence.

Market model inputs that typically move revenue

• Eligible prevalence/incidence for the underlying condition.
• Treatment initiation rate (how many diagnosed patients start the drug).
• Line-of-therapy mix (first-line vs later lines).
• Persistence (treatment duration and discontinuation).

Note: A complete, accurate market and financial trajectory requires exact product definition (brand spelling, strength, formulation, approval geography) and confirmed FDA/EMA identifiers. Without those specifics, revenue and adoption cannot be mapped to actual commercial performance.

How does ITOVEBI’s pricing and reimbursement impact net sales trajectory?

Net sales are driven by (a) list price, (b) realized discounts/rebates, (c) coverage, and (d) patient access programs. In specialty pharma, early revenue variance is usually a reimbursement and access story.

Key reimbursement mechanics

• Commercial payer formularies: preferred status yields higher utilization.
• Prior authorization (PA): strict criteria reduce early uptake unless evidence aligns to payer policy.
• Step edits: requirements to fail standard of care delay starts.
• Centers of Excellence (CoE) and provider contracting: can accelerate or cap early diffusion.

Financial impact paths

• Higher rebates and patient program spend lower net price and can shift gross margin even when unit volumes rise.
• Non-covered uses (off-label or restrictive label scope) cap addressable revenue.

When does ITOVEBI reach peak adoption and what adoption curves usually apply?

Specialty launches often follow an S-curve: early limited penetration, acceleration after payer coverage expands, then plateau as the eligible population saturates or competitors take share.

Adoption inflection points

• Label expansion (new indications or broader eligibility) increases the addressable population.
• Guideline placement: inclusion in national or specialty society guidance accelerates initiation.
• Safety monitoring evidence: additional post-marketing data can improve comfort among prescribers and payers.
• Competitive events: new entrants can cause share erosion before peak.

Metrics investors track

• Prescriptions or units sold through channels.
• TRx share (if measurable) and site-of-care share.
• Channel inventory (to detect pull-forward or stocking).

Note: Specific timeline and peak adoption estimates cannot be produced accurately without confirmed launch date, formulation, and marketed indication(s).

What patent estate protects ITOVEBI, and how strong is the protection against generics and biosimilars?

Revenue risk for ITOVEBI is tied to the patent stack around (1) composition, (2) formulation and delivery, (3) method of use, and (4) manufacturing. Patent strength determines whether generic or biosimilar entry is blocked or delayed.

How to evaluate strength

• Number of active patents by jurisdiction
• Remaining term of the latest-expiring claims
• Claim breadth (does it cover multiple analogs/formulations or only one specific embodiment)
• Exclusivity overlap (regulatory exclusivities can extend effective market life beyond patent expiry)

Generic and biosimilar exposure

• Small molecule: FDA ANDA pathway and Paragraph IV challenges matter.
• Biologic: BLA biosimilar pathway; exclusivity and data/CMC barriers matter.

Note: A defensible patent-and-expiry mapping requires the verified ITOVEBI active ingredient, regulatory status, and the associated Orange Book/Bolar listings. Those data are not provided here.

What is the Orange Book status of ITOVEBI and which FDA listings matter for competition?

Orange Book status determines the legal landscape for ANDA applicants: patent numbers listed, expiries, and exclusivity.

Competitive entry pathways affected by listings

• Orange Book patents with unexpired terms block a generic filing without authorization.
• Market exclusivity (if applicable) blocks FDA approval even when patents are addressed.

Note: Orange Book listings cannot be stated accurately without the exact FDA NDA/BLA number for ITOVEBI.

What patent litigation affects ITOVEBI and how does it influence launch timing for competitors?

In specialty markets, Paragraph IV and related settlements typically dictate first generic timing and whether entrants launch “at risk” or later under a negotiated timetable.

Litigation outcomes that move revenue

• Court injunctions delaying FDA approval
• Settlement “carve-outs” allowing partial entry
• Design-around success (competitor changes formulation or claims to avoid infringement)

Note: Litigation events cannot be listed without the case docket and asserted patents tied to the specific ITOVEBI application.

How does ITOVEBI compare with competing drugs in the same therapeutic area?

Competitive dynamics are driven by (1) efficacy, (2) safety, (3) convenience, (4) incremental cost-effectiveness, and (5) payer comfort.

Comparison framework

• Efficacy endpoints: response rate, time-to-response, durability
• Safety: discontinuation rates, serious adverse events, monitoring burden
• Treatment regimen: dosing frequency, duration, administration logistics
• Value proposition: cost per responder and budget impact at the payer level

Share drivers

• Provider adoption: if key opinion leaders shift practice quickly, early share concentrates with the dominant brand.
• Payer leverage: formulary positioning can determine where prescribers start.

Note: Specific competitive comparisons cannot be completed without confirmed indication and the competing product set.

What generic entry risks exist for ITOVEBI and what would trigger them?

Generic entry risks depend on the timing of:

• Patent expiry and claim loss (invalidations or narrowing constructions)
• Regulatory exclusivity cliffs
• Judicial outcomes that remove the “at risk” barrier
• Commercial readiness of a generic sponsor (manufacturing capacity and CMC acceptance)

Trigger events

• Paragraph IV filings signaling anticipated launch windows
• Settlement agreements setting negotiated entry dates
• CMC readiness and FDA correspondence indicating likelihood of approval

Note: Generic entry risk windows require verified patent expiry dates and any Paragraph IV activity.

How does ITOVEBI’s manufacturing and CMC readiness affect supply, margins, and continuity of sales?

Supply stability is a direct revenue driver. Shortages reduce TRx capture and can permanently shift prescriber habits if patients switch early.

CMC levers that affect gross margin

• Single-source raw materials create disruption risk.
• Yield and batch release impact cost of goods sold (COGS).
• Scale-up timing affects ability to meet demand without margin dilution.

Market impact

• Allocations can slow uptake even when demand exists.
• Backorders create “lost prescriptions” that competitors take.

Where does ITOVEBI sit on the financial trajectory curve: ramp, maturity, and downside scenarios?

Revenue trajectory in specialty drugs generally follows:

1. launch ramp,
2. payer-driven acceleration,
3. maturity plateau, then
4. erosion post-competition.

Downside scenarios that compress earnings

• Net price erosion from increased rebate pressure or mandated discounts.
• Volume misses from restrictive coverage criteria.
• Safety signal leading to label narrowing or reduced utilization.
• Earlier-than-expected competition due to patent weakness or successful design-arounds.

Upside scenarios

• Broader label or guideline adoption expanding patient pool.
• Improved persistence increasing lifetime treatment share.
• Favorable real-world outcomes that drive payer policy shifts.

Note: A quantified financial trajectory requires confirmed company-level reporting tied to the actual product and sales line items.

What revenue exposure does ITOVEBI create by geography and channel?

Geography and channel mix are critical because net price, access pathways, and pricing regulation differ:

• US: payer rebates, PA, and specialty pharmacy vs buy-and-bill dynamics.
• EU/UK: HTA decisions (NICE/SMC) can heavily condition adoption.
• Rest of World: tender pricing and constrained reimbursement can limit scale.

Channel dynamics

• Hospital buy-and-bill: revenue timing tied to billing cycles and administration documentation.
• Specialty pharmacy: revenue depends on fulfillment, copay support utilization, and adherence.

Key Takeaways

• ITOVEBI’s financial trajectory is primarily determined by payer coverage, net pricing, and the pace of clinical adoption aligned to label scope and treatment setting.
• Patent estate strength and Orange Book or biosimilar-relevant legal listings govern competitive entry risk and, by extension, revenue duration.
• Manufacturing and CMC execution affects supply stability, which can lock in or lose prescriber share early.
• Quantified timelines for uptake, net sales, and exclusivity cliffs require verified product identifiers (NDA/BLA, indication, formulation/strength) and corresponding FDA legal/regulatory listings.

FAQs

1. How do payers decide formulary placement for high-cost specialty drugs like ITOVEBI?
2. What indicators on FDA legal listings (Orange Book, exclusivity) forecast generic or biosimilar entry timing for ITOVEBI?
3. How do Paragraph IV filings typically change revenue projections for new specialty launches?
4. What role do HTA bodies (NICE/SMC) play in shaping ITOVEBI’s UK uptake and net price?
5. How does site-of-care (hospital buy-and-bill vs specialty pharmacy) change ITOVEBI sales cadence and margin?

References (APA)

1. [Not available: no verifiable sources were provided for ITOVEBI identity, regulatory status, or sales figures.]